GILEAD SCIENCES SL

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.

Yuhan Corporation tops net buying for top 1% investors at 9:30 a.m., driven by FDA approvals and collaborations. HPSP, a semiconductor equipment supplier, also sees net buying. HLB, Celltrion, and T&L experience net sales.

Opthea Limited has made executive leadership changes in finance and commercial areas, and hired senior staff in biometrics, clinical operations, and market access. These changes are in preparation for the anticipated clinical trial data in 2025. Key hires include Dan Geffken as interim CFO, Mike Campbell as CCO, Dayong Li as SVP of Biometrics, Jen Watts as VP of Global Clinical Operations, and Anthony Bonifazio as VP of Market Access.

Dato-DXd plus durvalumab achieved a 50% pathologic complete response (pCR) rate in stage II/III high-risk HER2-negative breast cancer patients, according to the I-SPY 2.2 trial. The study emphasizes evaluating treatment response per response predictive subtype (RPS) and suggests further investigation in immune-positive and hormone receptor (HR)-negative/DNA damage repair deficiency (DRD)-negative subtypes. The combination's efficacy was supported by the BEGONIA trial, showing a 79% objective response rate in metastatic triple-negative breast cancer. The I-SPY 2.2 trial design uses RPS to optimize drug assignment, aiming to improve efficacy and minimize toxicity.

The Liberal National Coalition believes in Australia's life sciences and biotech sector's potential, highlighting strengths like health research, clinical trials, and biotech companies. The speaker criticizes current Labor Government policies for hindering sector growth, citing funding cuts and anti-business policies. They advocate for a Coalition approach focusing on commercializing research, attracting private investment, leveraging sector strengths, and avoiding picking winners, as demonstrated in past policies like the Medical Research Future Fund and National Innovation and Science Agenda.

AbbVie, a pharmaceutical firm with strong immunology and oncology portfolios, is compared against key competitors in the Biotechnology industry. The analysis reveals AbbVie's high Price to Earnings (64.53), Price to Book (50.28), and Price to Sales (6.22) ratios, suggesting a potentially overvalued stock. However, its high Return on Equity (18.4%), EBITDA ($5.0B), and gross profit ($10.26B) indicate strong profitability and operational efficiency. The company's low revenue growth (4.31%) compared to the industry average (28.79%) raises concerns about future performance.

Gilead's research program has achieved advancements once thought impossible over 30 years.

Managed access offers patients with serious conditions access to investigational medical products when no alternative therapies exist. Clinical trials are preferred for data on efficacy and safety. When trials are unavailable, individual patient use or expanded access protocols are considered. Risks and benefits of investigational products should be carefully considered.

FDA grants Gilead Sciences' Livdelzi (seladelpar) accelerated approval for treating PBC in adults intolerant or unresponsive to UDCA. Livdelzi, a PPAR delta agonist, showed significant improvement in liver disease markers and reduced pruritus in the RESPONSE study, with potential for continued approval pending further trials.

Our 35-year history of success drives us to innovate in virology, oncology, and inflammation, transforming global health challenges like HIV and hepatitis C, and poised for revolutionary therapies.